Metoprolol 100 mg tablets 30

1 tablet contains:

Active substances: metoprolol tartrate 100 mg.

Excipients: silicon dioxide colloidal anhydrous, microcrystalline cellulose, sodium carboxymethyl starch (type A), magnesium stearate.

Shell composition: hypromellose, polysorbate 80, talc, titanium dioxide (E171).

Cardioselective beta1-blocker without internal sympathomimetic activity. It has a hypotensive, antianginal and antiarrhythmic effect. Reduces the automatism of the sinus node, reduces heart rate, slows down AV-conduction, reduces contractility and excitability of the myocardium, reduces the minute volume of the heart, reduces the need for myocardium in oxygen. Suppresses stimulating effect of catecholamines on the heart during physical and psycho-emotional stress.

It causes a hypotensive effect, which stabilizes by the end of the 2nd week of course use. With angina pectoris, metoprolol reduces the frequency and severity of attacks. Normalizes heart rate with supraventricular tachycardia and atrial fibrillation. With myocardial infarction, it helps to limit the zone of ischemia of the heart muscle and reduces the risk of developing fatal arrhythmias, reduces the possibility of relapse of myocardial infarction. When used in medium therapeutic doses, it has a less pronounced effect on the smooth muscles of the bronchi and peripheral arteries than non-selective beta-blockers.

After oral administration, metoprolol is quickly and almost completely absorbed from the gastrointestinal tract, Cmax of the active substance in the blood plasma is reached after 1-2 h. After absorption, metoprolol is largely exposed to the effect of the "first pass" through the liver. It is intensively metabolized in the liver with the participation of isoenzymes of the cytochrome P450 system with the formation of non-cationic metabolites. T1 / 2 metoprolol from plasma is 3-4 hours and does not change during the course of treatment. More than 95% of the dose taken is excreted by the kidneys, of which only 3% are unchanged.

Hypersensitivity, cardiogenic shock, AV blockade of II and III degrees, sinoatrial blockade, chronic (in the stage of decompensation) heart failure, syndrome of weakness of the sinus node, pronounced sinus bradycardia (heart rate less than 60 beats / min), Prinzmetal's angina, acute myocardial infarction (heart rate less than 45 beats / min, PQ interval more than 0.24 seconds, systolic blood pressure less than 100 mm Hg).

Pregnancy, lactation. Simultaneous intravenous administration of blockers of "slow" calcium channels such as verapamil. Age up to 18 years. Pheochromocytoma. patients receiving long-term or intermittent therapy with inotropic agents and acting on beta-adrenergic receptors.

When taken orally, the average dose is 100 mg / day in 1-2 doses. If necessary, the daily dose is gradually increased to 200 mg.

Maximum doses: when taken orally, the daily dose is 400 mg.

From the cardiovascular system: bradycardia, arterial hypotension, AV-conduction disorders, the appearance of symptoms of heart failure are possible.

From the digestive side systems: at the beginning of therapy, dry mouth, nausea, vomiting, diarrhea, constipation are possible; in some cases - impaired liver function.

From the side of the central nervous system and the peripheral nervous system: at the beginning of therapy, weakness, fatigue, dizziness, headache, muscle cramps, a feeling of cold and paresthesia in the limbs are possible; possible decrease in the secretion of tear fluid, conjunctivitis, rhinitis, depression, sleep disorders, nightmares.

From the hematopoietic system: in some cases - thrombocytopenia.

From the endocrine system: hypoglycemic conditions in patients with diabetes mellitus.

From the respiratory system: predisposed patients may experience symptoms of bronchial obstruction.

Allergic reactions: skin rash, itching.